Amgen Inc on Wednesday said third-quarter adjusted profit rose 17% due to stronger sales of drugs such as osteoporosis treatment Prolia and psoriasis medication Otezla, bucking challenges from lower ...
India-based Biocon’s biosimilars subsidiary has reached a settlement and license agreement with Amgen that clears the path ...
Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for ...
Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer that has spread to the bone.
Shanghai Henlius Biotech, Inc., and Organon announced the European Commission (EC) has granted marketing authorization for Bildyos (denosumab) injection 60 mg/mL and Bilprevda (denosumab) injection ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s ...
REYKJAVIK - Alvotech (NASDAQ:ALVO), a $2.47 billion market cap biotech company trading near its 52-week low of $7.35, announced Monday that the European Medicines Agency’s Committee for Medicinal ...
REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has successfully completed the Phase-3 clinical study of its Denosumab Biosimilar, marking a major milestone in the treatment of osteoporosis. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback